GVHD/CYDY https://seekingalpha.com/article/4397
Post# of 153834
(Total Views: 541)
Posted On: 01/04/2021 7:12:56 AM
GVHD/CYDY
https://seekingalpha.com/article/4397128-merc...erapeutics
"Leronlimab
The top drug in GvHD is leronlimab which is made by CytoDyn Inc. (OTCQB:CYDY). Their preclinical results showed a cure in mice and the drug itself has an exceptional safety profile. They injected human stem cells in mice which is supposed to lead to a 100% mortality of the mice and instead all the mice lived and got healthier. They actually did the experiment twice because the results were so extraordinary. They dosed only one person in GvHD, but that data has not been announced.
The more important issue is how the drug performed with COVID-19. In CytoDyn's Phase 2 with mild to moderate patients, they had a clinically significant reduction in clinical symptom score which was 90% versus 71% on placebo. They also had a statistically significant reduction in the National Early Warning Score 2 (NEWS2) scale on Day 3 and Day 14 (p<0.03 and p<0.02). This means that the leronlimab group was twice as likely to have an improvement in their score over the placebo group."
https://seekingalpha.com/article/4397128-merc...erapeutics
"Leronlimab
The top drug in GvHD is leronlimab which is made by CytoDyn Inc. (OTCQB:CYDY). Their preclinical results showed a cure in mice and the drug itself has an exceptional safety profile. They injected human stem cells in mice which is supposed to lead to a 100% mortality of the mice and instead all the mice lived and got healthier. They actually did the experiment twice because the results were so extraordinary. They dosed only one person in GvHD, but that data has not been announced.
The more important issue is how the drug performed with COVID-19. In CytoDyn's Phase 2 with mild to moderate patients, they had a clinically significant reduction in clinical symptom score which was 90% versus 71% on placebo. They also had a statistically significant reduction in the National Early Warning Score 2 (NEWS2) scale on Day 3 and Day 14 (p<0.03 and p<0.02). This means that the leronlimab group was twice as likely to have an improvement in their score over the placebo group."
(0)
(0)